{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:34:19Z","timestamp":1787578459919,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001458","name":"American Kennel Club Canine Health Foundation","doi-asserted-by":"publisher","award":["03181-A"],"award-info":[{"award-number":["03181-A"]}],"id":[{"id":"10.13039\/100001458","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Qankorey Biotechnology Co. Ltd"},{"DOI":"10.13039\/501100020481","name":"Australian and New Zealand Society for Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001777","name":"The University of Wollongong","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001777","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The P2X7 receptor (or P2X7) is an ATP-gated ion channel with important roles in the immune and other body systems. Much has been garnered about P2X7 using the first published anti-human P2X7 monoclonal antibody (mAb) (clone L4). This mAb can be used to impair P2X7 channel and pore activity and events downstream of P2X7 activation in vitro and in vivo. Immunolabelling with this mAb has been used in flow and mass cytometry, confocal microscopy and immunohistochemistry to help establish the presence of P2X7 on human leukocytes and other primary cell types, as well as various malignant cell lines. This mAb has been applied to immunoprecipitate P2X7 to identify co-associated molecules to help uncover novel roles of the receptor such as phagocytosis. Recently, this mAb has been shown to mediate complement-dependent cytotoxicity, offering a new avenue of limiting P2X7-mediated processes by depleting P2X7\n                    <jats:sup>+<\/jats:sup>\n                    cells. Finally, this mAb has been used to identify and characterise polymorphic and other variants of P2X7. This article will discuss the origins and various applications of the anti-P2X7 mAb (clone L4). As an early user of this mAb and pioneer of other purinergic technologies, this article is a tribute to the late Francesco Di Virgilio.\n                  <\/jats:p>","DOI":"10.1007\/s11302-026-10176-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:17:08Z","timestamp":1784913428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The P2X7 receptor: insights from the murine monoclonal antibody clone L4"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-686X","authenticated-orcid":false,"given":"Ronald","family":"Sluyter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-3183","authenticated-orcid":false,"given":"Amal","family":"Elhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-1326","authenticated-orcid":false,"given":"Rachael","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6242-3944","authenticated-orcid":false,"given":"Debbie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-6781","authenticated-orcid":false,"given":"Leanne","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4971-2773","authenticated-orcid":false,"given":"Kristen K.","family":"Skarratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4637-7391","authenticated-orcid":false,"given":"Stephen J.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-4453","authenticated-orcid":false,"given":"Ben J.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"10176_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes P, M\u00fcller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F (2021) Update of P2X receptor properties and their pharmacology: IUPHAR review 30. Br J Pharmacol 178:489\u2013514. https:\/\/doi.org\/10.1111\/bph.15299","journal-title":"Br J Pharmacol"},{"key":"10176_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11302-026-10135-9","volume":"22","author":"S Falzoni","year":"2026","unstructured":"Falzoni S, Giuliani AL, Adinolfi E, Coutinho-Silva R, Illes P, Robson SC, Tang Y, Ulrich H, Kennedy C (2026) In tribute to Francesco Di Virgilio, a great scientist and a wonderful friend. Purinergic Signal 22:20. https:\/\/doi.org\/10.1007\/s11302-026-10135-9","journal-title":"Purinergic Signal"},{"key":"10176_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","volume":"151","author":"E Adinolfi","year":"2018","unstructured":"Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F (2018) The P2X7 receptor: a main player in inflammation. Biochem Pharmacol 151:234\u2013244. https:\/\/doi.org\/10.1016\/j.bcp.2017.12.021","journal-title":"Biochem Pharmacol"},{"key":"10176_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47:15\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.020","journal-title":"Immunity"},{"key":"10176_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.tips.2007.07.002","volume":"28","author":"F Di Virgilio","year":"2007","unstructured":"Di Virgilio F (2007) Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci 28:465\u2013472. https:\/\/doi.org\/10.1016\/j.tips.2007.07.002","journal-title":"Trends Pharmacol Sci"},{"key":"10176_CR6","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","volume":"176","author":"D Ferrari","year":"2006","unstructured":"Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877\u20133883. https:\/\/doi.org\/10.4049\/jimmunol.176.7.3877","journal-title":"J Immunol"},{"key":"10176_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11302-005-6322-x","volume":"1","author":"E Adinolfi","year":"2005","unstructured":"Adinolfi E, Pizzirani C, Idzko M, Panther E, Norgauer J, Di Virgilio F, Ferrari D (2005) P2X7 receptor: Death or life? Purinergic Signal 1:219\u2013227. https:\/\/doi.org\/10.1007\/s11302-005-6322-x","journal-title":"Purinergic Signal"},{"key":"10176_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601\u2013618. https:\/\/doi.org\/10.1038\/s41568-018-0037-0","journal-title":"Nat Rev Cancer"},{"key":"10176_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.mcb.2025.02.014","volume":"199","author":"M Tarantini","year":"2025","unstructured":"Tarantini M, Vultaggio-Poma V, Falzoni S, Adinolfi E, Giuliani AL, Di Virgilio F (2025) In-vivo measurement of the extracellular ATP concentration by bio-luminescence: The pmeLUC probe. Methods Cell Biol 199:53\u201366. https:\/\/doi.org\/10.1016\/bs.mcb.2025.02.014","journal-title":"Methods Cell Biol"},{"key":"10176_CR10","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood.V92.10.3521","volume":"92","author":"G Buell","year":"1998","unstructured":"Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, Gretener D, Grahames C, Kaur R, Kosco-Vilbois MH, Humphrey PP (1998) Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92:3521\u20133528","journal-title":"Blood"},{"key":"10176_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/jlb.66.5.723","volume":"66","author":"F Di Virgilio","year":"1999","unstructured":"Di Virgilio F, Falzoni S, Chiozzi P, Sanz JM, Ferrari D, Buell GN (1999) ATP receptors and giant cell formation. J Leukoc Biol 66:723\u2013726. https:\/\/doi.org\/10.1002\/jlb.66.5.723","journal-title":"J Leukoc Biol"},{"key":"10176_CR12","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1091\/mbc.11.9.3169","volume":"11","author":"S Falzoni","year":"2000","unstructured":"Falzoni S, Chiozzi P, Ferrari D, Buell G, Di Virgilio F (2000) P2X7 receptor and polykarion formation. Mol Biol Cell 11:3169\u20133176. https:\/\/doi.org\/10.1091\/mbc.11.9.3169","journal-title":"Mol Biol Cell"},{"key":"10176_CR13","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1096\/fj.00-0031com","volume":"14","author":"D Ferrari","year":"2000","unstructured":"Ferrari D, La Sala A, Chiozzi P, Morelli A, Falzoni S, Girolomoni G, Idzko M, Dichmann S, Norgauer J, Di Virgilio F (2000) The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J 14:2466\u20132476. https:\/\/doi.org\/10.1096\/fj.00-0031com","journal-title":"FASEB J"},{"key":"10176_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/B978-0-443-30250-3.00018-7","volume-title":"ATP: from neurotransmission to cancer therapy","author":"WG Junger","year":"2026","unstructured":"Junger WG, Yegutkin GY (2026) Extracellular ATP and adaptive immunity. In: Sluyter R, Cederholm JME, Stokes L, Ulrich H, Vlajkovic SM, Tang Y (eds) ATP: from neurotransmission to cancer therapy. Academic Press, London, UK, pp 647\u2013665. https:\/\/doi.org\/10.1016\/B978-0-443-30250-3.00018-7"},{"key":"10176_CR15","doi-asserted-by":"publisher","unstructured":"Lopez-Castejon G and Stokes L (2026) Extracellular ATP and innate immune cells. In: Sluyter R, Cederholm JME, Stokes L, Ulrich H, Vlajkovic SM and Tang Y (ed) ATP: From Neurotransmission to Cancer Therapy. Academic Press, London, UK, pp 627\u2013645. https:\/\/doi.org\/10.1016\/B978-0-443-30250-3.00014-X","DOI":"10.1016\/B978-0-443-30250-3.00014-X"},{"key":"10176_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-9717-6_8","volume":"2041","author":"N Schwarz","year":"2020","unstructured":"Schwarz N, Junge M, Haag F, Koch-Nolte F (2020) Flow cytometry of membrane purinoreceptors. Methods Mol Biol 2041:117\u2013136. https:\/\/doi.org\/10.1007\/978-1-4939-9717-6_8","journal-title":"Methods Mol Biol"},{"key":"10176_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-0716-2384-8_5","volume":"2510","author":"A Elhage","year":"2022","unstructured":"Elhage A, Turner RJ, Cuthbertson P, Watson D, Sluyter R (2022) Preparation of the murine anti-human P2X7 receptor monoclonal antibody (Clone L4). Methods Mol Biol 2510:77\u201398. https:\/\/doi.org\/10.1007\/978-1-0716-2384-8_5","journal-title":"Methods Mol Biol"},{"key":"10176_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-0716-2384-8_15","volume":"2510","author":"L Hurtado-Navarro","year":"2022","unstructured":"Hurtado-Navarro L, Baroja-Mazo A, Pelegr\u00edn P (2022) Characterization of P2X7 receptors in human blood cells. Methods Mol Biol 2510:279\u2013290. https:\/\/doi.org\/10.1007\/978-1-0716-2384-8_15","journal-title":"Methods Mol Biol"},{"key":"10176_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-0716-2384-8_6","volume":"2510","author":"T St\u00e4hler","year":"2022","unstructured":"St\u00e4hler T, Danquah W, Demeules M, Gond\u00e9 H, Hardet R, Haag F, Adriouch S, Koch-Nolte F, Menzel S (2022) Development of Antibody and Nanobody Tools for P2X7. Methods Mol Biol 2510:99\u2013127. https:\/\/doi.org\/10.1007\/978-1-0716-2384-8_6","journal-title":"Methods Mol Biol"},{"key":"10176_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8463","volume":"8","author":"W Danquah","year":"2016","unstructured":"Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M, Iacenda D, Knop JH, Hammel A, Bergmann P, Schwarz N, Assun\u00e7\u00e3o J, Rotthier W, Haag F, Tolosa E, Bannas P, Bou\u00e9-Grabot E, Magnus T, Laeremans T, Stortelers C, Koch-Nolte F (2016) Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med 8:366ra162. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8463","journal-title":"Sci Transl Med"},{"key":"10176_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451196","volume":"55","author":"A Elhage","year":"2025","unstructured":"Elhage A, Watson D, Sluyter R (2025) The anti-human P2X7 monoclonal antibody (clone L4) can mediate complement-dependent cytotoxicity of human leukocytes. Eur J Immunol 55:e202451196. https:\/\/doi.org\/10.1002\/eji.202451196","journal-title":"Eur J Immunol"},{"key":"10176_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/stem.1864","volume":"33","author":"MD Lovelace","year":"2015","unstructured":"Lovelace MD, Gu BJ, Eamegdool SS, Weible MW 2nd, Wiley JS, Allen DG, Chan-Ling T (2015) P2X7 receptors mediate innate phagocytosis by human neural precursor cells and neuroblasts. Stem Cells 33:526\u2013541. https:\/\/doi.org\/10.1002\/stem.1864","journal-title":"Stem Cells"},{"key":"10176_CR23","doi-asserted-by":"publisher","first-page":"C1189","DOI":"10.1152\/ajpcell.2000.279.4.C1189","volume":"279","author":"BJ Gu","year":"2000","unstructured":"Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS (2000) Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors. Am J Physiol Cell Physiol 279:C1189-1197. https:\/\/doi.org\/10.1152\/ajpcell.2000.279.4.C1189","journal-title":"Am J Physiol Cell Physiol"},{"key":"10176_CR24","doi-asserted-by":"publisher","unstructured":"Elhage A, Cuthbertson P, Sligar C, Watson D, Sluyter R (2023) A species-specific anti-human P2X7 monoclonal antibody reduces graft-versus-host disease in humanised mice. Pharmaceutics 15:2263. https:\/\/doi.org\/10.3390\/pharmaceutics15092263","DOI":"10.3390\/pharmaceutics15092263"},{"key":"10176_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1096\/fj.10-169854","volume":"25","author":"P Pellegatti","year":"2011","unstructured":"Pellegatti P, Falzoni S, Donvito G, Lemaire I, Di Virgilio F (2011) P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J 25:1264\u20131274. https:\/\/doi.org\/10.1096\/fj.10-169854","journal-title":"FASEB J"},{"key":"10176_CR26","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.4049\/jimmunol.0804265","volume":"183","author":"R Rizzo","year":"2009","unstructured":"Rizzo R, Ferrari D, Melchiorri L, Stignani M, Gulinelli S, Baricordi OR, Di Virgilio F (2009) Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J Immunol 183:4302\u20134311. https:\/\/doi.org\/10.4049\/jimmunol.0804265","journal-title":"J Immunol"},{"key":"10176_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11302-022-09894-y","volume":"18","author":"C Drysdale","year":"2022","unstructured":"Drysdale C, Park K, Vessey KA, Huang X, Caruso E, Li Y, Wong J, Wiley JS, Fletcher E, Guymer RH, Gu BJ (2022) P2X7-mediated alteration of membrane fluidity is associated with the late stages of age-related macular degeneration. Purinergic Signal 18:469\u2013479. https:\/\/doi.org\/10.1007\/s11302-022-09894-y","journal-title":"Purinergic Signal"},{"key":"10176_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.icb.7100005","volume":"85","author":"AN Shemon","year":"2007","unstructured":"Shemon AN, Sluyter R, Wiley JS (2007) Rottlerin inhibits P2X7 receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes. Immunol Cell Biol 85:68\u201372. https:\/\/doi.org\/10.1038\/sj.icb.7100005","journal-title":"Immunol Cell Biol"},{"key":"10176_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2384-8_2","volume":"2510","author":"CE M\u00fcller","year":"2022","unstructured":"M\u00fcller CE, Namasivayam V (2022) Agonists, antagonists, and modulators of P2X7 receptors. Methods Mol Biol 2510:31\u201352. https:\/\/doi.org\/10.1007\/978-1-0716-2384-8_2","journal-title":"Methods Mol Biol"},{"key":"10176_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11302-023-09955-w","volume":"19","author":"BJ Gu","year":"2023","unstructured":"Gu BJ, Fuller SJ, Skarratt KK, Stokes L, Wiley MJ, Sluyter R (2023) James Saville Wiley (1936\u20132022): pioneer of purinergic research in Australia and abroad. Purinergic Signal 19:581\u2013585. https:\/\/doi.org\/10.1007\/s11302-023-09955-w","journal-title":"Purinergic Signal"},{"key":"10176_CR31","doi-asserted-by":"publisher","first-page":"C430","DOI":"10.1152\/ajpcell.00079.2009","volume":"297","author":"BJ Gu","year":"2009","unstructured":"Gu BJ, Rathsam C, Stokes L, McGeachie AB, Wiley JS (2009) Extracellular ATP dissociates nonmuscle myosin from P2X7 complex: this dissociation regulates P2X7 pore formation. Am J Physiol Cell Physiol 297:C430-439. https:\/\/doi.org\/10.1152\/ajpcell.00079.2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10176_CR32","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1111\/bph.14470","volume":"175","author":"BJ Gu","year":"2018","unstructured":"Gu BJ, Wiley JS (2018) P2X7 as a scavenger receptor for innate phagocytosis in the brain. Br J Pharmacol 175:4195\u20134208. https:\/\/doi.org\/10.1111\/bph.14470","journal-title":"Br J Pharmacol"},{"key":"10176_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","volume":"24","author":"DC Mastellos","year":"2024","unstructured":"Mastellos DC, Hajishengallis G, Lambris JD (2024) A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol 24:118\u2013141. https:\/\/doi.org\/10.1038\/s41577-023-00926-1","journal-title":"Nat Rev Immunol"},{"key":"10176_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/thno.66274","volume":"12","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Falzoni S, Chiozzi P, Sarti AC, Adinolfi E, Giuliani AL, S\u00e1nchez-Melgar A, Boldrini P, Zanoni M, Tesei A, Pinton P, Di Virgilio F (2022) Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation. Theranostics 12:859\u2013874. https:\/\/doi.org\/10.7150\/thno.66274","journal-title":"Theranostics"},{"key":"10176_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/imm.13374","volume":"164","author":"SR Adhikary","year":"2021","unstructured":"Adhikary SR, Cuthbertson P, Nicholson L, Bird KM, Sligar C, Hu M, O\u2019Connell PJ, Sluyter R, Alexander SI, Watson D (2021) Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model. Immunology 164:332\u2013347. https:\/\/doi.org\/10.1111\/imm.13374","journal-title":"Immunology"},{"key":"10176_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","volume":"157","author":"MA King","year":"2009","unstructured":"King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL (2009) Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157:104\u2013118. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03933.x","journal-title":"Clin Exp Immunol"},{"key":"10176_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jim.2017.03.021","volume":"446","author":"MK Verma","year":"2017","unstructured":"Verma MK, Clemens J, Burzenski L, Sampson SB, Brehm MA, Greiner DL, Shultz LD (2017) A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods 446:47\u201353. https:\/\/doi.org\/10.1016\/j.jim.2017.03.021","journal-title":"J Immunol Methods"},{"key":"10176_CR38","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.bbagen.2010.07.001","volume":"1800","author":"AW Farrell","year":"2010","unstructured":"Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, Ranson M, Sluyter R (2010) P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta 1800:1173\u20131182. https:\/\/doi.org\/10.1016\/j.bbagen.2010.07.001","journal-title":"Biochim Biophys Acta"},{"key":"10176_CR39","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1096\/fj.09-150862","volume":"24","author":"L Stokes","year":"2010","unstructured":"Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, Wiley JS (2010) Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 24:2916\u20132927. https:\/\/doi.org\/10.1096\/fj.09-150862","journal-title":"FASEB J"},{"key":"10176_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093058","volume":"9","author":"A Bhaskaracharya","year":"2014","unstructured":"Bhaskaracharya A, Dao-Ung P, Jalilian I, Spildrejorde M, Skarratt KK, Fuller SJ, Sluyter R, Stokes L (2014) Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. PLoS ONE 9:e93058. https:\/\/doi.org\/10.1371\/journal.pone.0093058","journal-title":"PLoS ONE"},{"key":"10176_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1152\/physiolgenomics.00195.2013","volume":"46","author":"M Spildrejorde","year":"2014","unstructured":"Spildrejorde M, Bartlett R, Stokes L, Jalilian I, Peranec M, Sluyter V, Curtis BL, Skarratt KK, Skora A, Bakhsh T, Seavers A, McArthur JD, Dowton M, Sluyter R (2014) R270C polymorphism leads to loss of function of the canine P2X7 receptor. Physiol Genomics 46:512\u2013522. https:\/\/doi.org\/10.1152\/physiolgenomics.00195.2013","journal-title":"Physiol Genomics"},{"key":"10176_CR42","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/15257770.2017.1391395","volume":"36","author":"R Bartlett","year":"2017","unstructured":"Bartlett R, Stokes L, Curtis SJ, Curtis BL, Sluyter R (2017) Probenecid directly impairs activation of the canine P2X7 receptor. Nucleosides Nucleotides Nucleic Acids 36:736\u2013744. https:\/\/doi.org\/10.1080\/15257770.2017.1391395","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10176_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.40","volume":"5","author":"GJ Clark","year":"2016","unstructured":"Clark GJ, Kupresanin F, Fromm PD, Ju X, Muusers L, Silveira PA, Elgundi Z, Gasiorowski RE, Papadimitrious MS, Bryant C, Lee KM, Clarke CJ, Young JW, Chan A, Harman A, Botting R, Cabez\u00f3n R, Benitez-Ribas D, Brooks AE, Dunbar PR, Hart DN (2016) New insights into the phenotype of human dendritic cell populations. Clin Transl Immunol 5:e61. https:\/\/doi.org\/10.1038\/cti.2015.40","journal-title":"Clin Transl Immunol"},{"key":"10176_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.29","volume":"4","author":"SE Autenrieth","year":"2015","unstructured":"Autenrieth SE, Grimm S, Rittig SM, Gr\u00fcnebach F, Gouttefangeas C, B\u00fchring HJ (2015) Profiling of primary peripheral blood- and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 workshop in Wollongong, Australia. Clin Transl Immunol 4:e50. https:\/\/doi.org\/10.1038\/cti.2015.29","journal-title":"Clin Transl Immunol"},{"key":"10176_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.21","volume":"4","author":"S Gurka","year":"2015","unstructured":"Gurka S, Dirks S, Photiadis J, Kroczek RA (2015) Expression analysis of surface molecules on human thymic dendritic cells with the 10th HLDA workshop antibody panel. Clin Transl Immunol 4:e47. https:\/\/doi.org\/10.1038\/cti.2015.21","journal-title":"Clin Transl Immunol"},{"key":"10176_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s004410100372","volume":"304","author":"R Sluyter","year":"2001","unstructured":"Sluyter R, Barden JA, Wiley JS (2001) Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res 304:231\u2013236. https:\/\/doi.org\/10.1007\/s004410100372","journal-title":"Cell Tissue Res"},{"key":"10176_CR47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41388-018-0426-6","volume":"38","author":"SM Gilbert","year":"2019","unstructured":"Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S, Di Virgilio F, McNulty S, Lara R (2019) ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene 38:194\u2013208. https:\/\/doi.org\/10.1038\/s41388-018-0426-6","journal-title":"Oncogene"},{"key":"10176_CR48","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1074\/jbc.M507816200","volume":"281","author":"AN Shemon","year":"2006","unstructured":"Shemon AN, Sluyter R, Fernando SL, Clarke AL, Dao-Ung LP, Skarratt KK, Saunders BM, Tan KS, Gu BJ, Fuller SJ, Britton WJ, Petrou S, Wiley JS (2006) A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281:2079\u20132086. https:\/\/doi.org\/10.1074\/jbc.M507816200","journal-title":"J Biol Chem"},{"key":"10176_CR49","doi-asserted-by":"publisher","first-page":"e1462","DOI":"10.1002\/cti2.1462","volume":"12","author":"KA Kott","year":"2023","unstructured":"Kott KA, Chan AS, Vernon ST, Hansen T, Kim T, de Dreu M, Gunasegaran B, Murphy AJ, Patrick E, Psaltis PJ, Grieve SM, Yang JY, de St F, Groth B, McGuire HM, Figtree GA (2023) Mass cytometry analysis reveals altered immune profiles in patients with coronary artery disease. Clin Transl Immunology 12:e1462. https:\/\/doi.org\/10.1002\/cti2.1462","journal-title":"Clin Transl Immunology"},{"key":"10176_CR50","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1096\/fj.09-153601","volume":"24","author":"E Adinolfi","year":"2010","unstructured":"Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandon\u00e0 D, Markwardt F, Schmalzing G, Di Virgilio F (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24:3393\u20133404. https:\/\/doi.org\/10.1096\/fj.09-153601","journal-title":"FASEB J"},{"key":"10176_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.38","volume":"5","author":"G Clark","year":"2016","unstructured":"Clark G, Stockinger H, Balderas R, van Zelm MC, Zola H, Hart D, Engel P (2016) Nomenclature of CD molecules from the tenth human leucocyte differentiation antigen workshop. Clin Transl Immunol 5:e57. https:\/\/doi.org\/10.1038\/cti.2015.38","journal-title":"Clin Transl Immunol"},{"key":"10176_CR52","doi-asserted-by":"publisher","unstructured":"Xu C, Obers A, Qin M, Brandli A, Wong J, Huang X, Clatch A, Fayed A, Starkey G, D'Costa R, Gordon CL, Mak JYW, Fairlie DP, Beattie L, Mackay LK, Godfrey DI, Koay HF (2024) Selective regulation of IFN-\u03b3 and IL-4 co-producing unconventional T cells by purinergic signaling. J Exp Med 221:e20240354. https:\/\/doi.org\/10.1084\/jem.20240354","DOI":"10.1084\/jem.20240354"},{"key":"10176_CR53","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1038\/cti.2016.54","volume":"5","author":"D Damasceno","year":"2016","unstructured":"Damasceno D, Andr\u00e9s MP, van den Bossche WB, Flores-Montero J, de Bruin S, Teodosio C, van Dongen JJ, Orfao A, Almeida J (2016) Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells. Clin Transl Immunology 5:e100. https:\/\/doi.org\/10.1038\/cti.2016.54","journal-title":"Clin Transl Immunology"},{"key":"10176_CR54","doi-asserted-by":"publisher","unstructured":"Li Y, Huang X, Fowler C, Lim YY, Laws SM, Faux N, Doecke JD, Trounson B, Pertile K, Rumble R, Dor\u00e9 V, Villemagne VL, Rowe CC, Wiley JS, Maruff P, Masters CL and Gu BJ (2022) Identification of leukocyte surface P2X7 as a biomarker associated with Alzheimer's disease. Int J Mol Sci 23:7867. https:\/\/doi.org\/10.3390\/ijms23147867","DOI":"10.3390\/ijms23147867"},{"key":"10176_CR55","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/09537104.2021.1981844","volume":"33","author":"J Wong","year":"2022","unstructured":"Wong J, Gu BJ, Teoh H, Krupa M, Monif M, Slee M, Wiley JS (2022) Flow cytometry identifies an early stage of platelet apoptosis produced by agonists of the P2X1 and P2X7 receptors. Platelets 33:621\u2013631. https:\/\/doi.org\/10.1080\/09537104.2021.1981844","journal-title":"Platelets"},{"key":"10176_CR56","doi-asserted-by":"publisher","unstructured":"Sluyter R, Wiley JS (2014) P2X7 receptor activation induces CD62L shedding from human CD4+ and CD8+ T cells. Inflamm Cell Signal 1:e92. https:\/\/doi.org\/10.14800\/ics.92","DOI":"10.14800\/ics.92"},{"key":"10176_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bph.15951","volume":"180","author":"A Baroja-Mazo","year":"2023","unstructured":"Baroja-Mazo A, Pe\u00f1\u00edn-Franch A, Lucas-Ruiz F, de Torre-Minguela C, Alarc\u00f3n-Vila C, Hern\u00e1ndez-Caselles T, Pelegr\u00edn P (2023) P2X7 receptor activation impairs antitumour activity of natural killer cells. Br J Pharmacol 180:111\u2013128. https:\/\/doi.org\/10.1111\/bph.15951","journal-title":"Br J Pharmacol"},{"key":"10176_CR58","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/cells15090795","volume":"15","author":"A Elhage","year":"2026","unstructured":"Elhage A, Gunasegaran B, Smith N, Turner RJ, Watson D, McGuire HM, Sluyter R (2026) Mass cytometry reveals comparable proportions of leukocyte subsets and cell surface P2X7 or CD39 on human peripheral blood mononuclear cell samples isolated by Ficoll-Paque or SepMate tube density gradient centrifugation. Cells 15:795. https:\/\/doi.org\/10.3390\/cells15090795","journal-title":"Cells"},{"key":"10176_CR59","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/intimm\/dxf111","volume":"14","author":"R Sluyter","year":"2002","unstructured":"Sluyter R, Wiley JS (2002) Extracellular adenosine 5\u2019-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. Int Immunol 14:1415\u20131421. https:\/\/doi.org\/10.1093\/intimm\/dxf111","journal-title":"Int Immunol"},{"key":"10176_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.39","volume":"5","author":"A Ohradanova-Repic","year":"2016","unstructured":"Ohradanova-Repic A, Machacek C, Fischer MB, Stockinger H (2016) Differentiation of human monocytes and derived subsets of macrophages and dendritic cells by the HLDA10 monoclonal antibody panel. Clin Transl Immunol 5:e55. https:\/\/doi.org\/10.1038\/cti.2015.39","journal-title":"Clin Transl Immunol"},{"key":"10176_CR61","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.0022-202X.2005.23835.x","volume":"125","author":"JG Georgiou","year":"2005","unstructured":"Georgiou JG, Skarratt KK, Fuller SJ, Martin CJ, Christopherson RI, Wiley JS, Sluyter R (2005) Human epidermal and monocyte-derived langerhans cells express functional P2X receptors. J Invest Dermatol 125:482\u2013490. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23835.x","journal-title":"J Invest Dermatol"},{"key":"10176_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12964-014-0040-3","volume":"12","author":"M Kuhny","year":"2014","unstructured":"Kuhny M, Hochd\u00f6rfer T, Ayata CK, Idzko M, Huber M (2014) CD39 is a negative regulator of P2X7-mediated inflammatory cell death in mast cells. Cell Commun Signal 12:40. https:\/\/doi.org\/10.1186\/s12964-014-0040-3","journal-title":"Cell Commun Signal"},{"key":"10176_CR63","doi-asserted-by":"publisher","first-page":"C943","DOI":"10.1152\/ajpcell.2001.280.4.C943","volume":"280","author":"L Gudipaty","year":"2001","unstructured":"Gudipaty L, Humphreys BD, Buell G, Dubyak GR (2001) Regulation of P2X7 nucleotide receptor function in human monocytes by extracellular ions and receptor density. Am J Physiol Cell Physiol 280:C943-953. https:\/\/doi.org\/10.1152\/ajpcell.2001.280.4.C943","journal-title":"Am J Physiol Cell Physiol"},{"key":"10176_CR64","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.bbamem.2010.07.022","volume":"1798","author":"S Gadeock","year":"2010","unstructured":"Gadeock S, Tran JN, Georgiou JG, Jalilian I, Taylor RM, Wiley JS, Sluyter R (2010) TGF-\u03b21 prevents up-regulation of the P2X7 receptor by IFN-\u03b3 and LPS in leukemic THP-1 monocytes. Biochim Biophys Acta 1798:2058\u20132066. https:\/\/doi.org\/10.1016\/j.bbamem.2010.07.022","journal-title":"Biochim Biophys Acta"},{"key":"10176_CR65","doi-asserted-by":"publisher","unstructured":"Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis M, Andr\u00e4 I, Andreata F, Annunziato F, Arranz E, Bacher P, Bari S, Barnaba V, Barros-Martins J, Baumjohann D, Beccaria CG, Bernardo D, Boardman DA, Borger J, B\u00f6ttcher C, Brockmann L, Burns M, Busch DH, Cameron G, Cammarata I, Cassotta A, Chang Y, Chirdo FG, Christakou E, \u010ci\u010din-\u0160ain L, Cook L, Corbett AJ, Cornelis R, Cosmi L, Davey MS, De Biasi S, De Simone G, Del Zotto G, Delacher M, Di Rosa F, Di Santo J, Diefenbach A, Dong J, D\u00f6rner T, Dress RJ, Dutertre CA, Eckle SBG, Eede P, Evrard M, Falk CS, Feuerer M, Fillatreau S, Fiz-Lopez A, Follo M, Foulds GA, Fr\u00f6bel J, Gagliani N, Galletti G, Gangaev A, Garbi N, Garrote JA, Geginat J, Gherardin NA, Gibellini L, Ginhoux F, Godfrey DI, Gruarin P, Haftmann C, Hansmann L, Harpur CM, Hayday AC, Heine G, Hern\u00e1ndez DC, Herrmann M, Hoelsken O, Huang Q, Huber S, Huber JE, Huehn J, Hundemer M, Hwang WYK, Iannacone M, Ivison SM, J\u00e4ck HM, Jani PK, Keller B, Kessler N, Ketelaars S, Knop L, Knopf J, Koay HF, Kobow K, Kriegsmann K, Kristyanto H, Krueger A, Kuehne JF, Kunze-Schumacher H, Kvistborg P, Kwok I, Latorre D, Lenz D, Levings MK, Lino AC, Liotta F, Long HM, Lugli E, MacDonald KN, Maggi L, Maini MK, Mair F, Manta C, Manz RA, Mashreghi MF, Mazzoni A, McCluskey J, Mei HE, Melchers F, Melzer S, Mielenz D, Monin L, Moretta L, Multhoff G, Mu\u00f1oz LE, Mu\u00f1oz-Ruiz M, Muscate F, Natalini A, Neumann K, Ng LG, Niedobitek A, Niemz J, Almeida LN, Notarbartolo S, Ostendorf L, Pallett LJ, Patel AA, Percin GI, Peruzzi G, Pinti M, Pockley AG, Pracht K, Prinz I, Pujol-Autonell I, Pulvirenti N, Quatrini L, Quinn KM, Radbruch H, Rhys H, Rodrigo MB, Romagnani C, Saggau C, Sakaguchi S, Sallusto F, Sanderink L, Sandrock I, Schauer C, Scheffold A, Scherer HU, Schiemann M, Schildberg FA, Schober K, Schoen J, Schuh W, Sch\u00fcler T, Schulz AR, Schulz S, Schulze J, Simonetti S, Singh J, Sitnik KM, Stark R, Starossom S, Stehle C, Szelinski F, Tan L, Tarnok A, Tornack J, Tree TIM, van Beek JJP, van de Veen W, van Gisbergen K, Vasco C, Verheyden NA, von Borstel A, Ward-Hartstonge KA, Warnatz K, Waskow C, Wiedemann A, Wilharm A, Wing J, Wirz O, Wittner J, Yang JHM and Yang J (2021) Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol 51 2708\u20133145. https:\/\/doi.org\/10.1002\/eji.202170126","DOI":"10.1002\/eji.202170126"},{"key":"10176_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02052","volume":"10","author":"TP Hofer","year":"2019","unstructured":"Hofer TP, van de Loosdrecht AA, Stahl-Hennig C, Cassatella MA, Ziegler-Heitbrock L (2019) 6-Sulfo LacNAc (Slan) as a marker for non-classical monocytes. Front Immunol 10:2052. https:\/\/doi.org\/10.3389\/fimmu.2019.02052","journal-title":"Front Immunol"},{"key":"10176_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1287656","volume":"14","author":"N Tamassia","year":"2023","unstructured":"Tamassia N, Bianchetto-Aguilera F, Gasperini S, Grimaldi A, Montaldo C, Calzetti F, Gardiman E, Signoretto I, Castellucci M, Barnaba V, Tripodi M, Cassatella MA (2023) The slan antigen identifies the prototypical non-classical CD16+-monocytes in human blood. Front Immunol 14:1287656. https:\/\/doi.org\/10.3389\/fimmu.2023.1287656","journal-title":"Front Immunol"},{"key":"10176_CR68","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1016\/j.celrep.2017.11.079","volume":"21","author":"J Amores-Iniesta","year":"2017","unstructured":"Amores-Iniesta J, Barber\u00e0-Cremades M, Mart\u00ednez CM, Pons JA, Revilla-Nuin B, Mart\u00ednez-Alarc\u00f3n L, Di Virgilio F, Parrilla P, Baroja-Mazo A, Pelegr\u00edn P (2017) Extracellular ATP activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection. Cell Rep 21:3414\u20133426. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.079","journal-title":"Cell Rep"},{"key":"10176_CR69","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41467-019-10626-x","volume":"10","author":"JJ Mart\u00ednez-Garc\u00eda","year":"2019","unstructured":"Mart\u00ednez-Garc\u00eda JJ, Mart\u00ednez-Banaclocha H, Angosto-Bazarra D, de Torre-Minguela C, Baroja-Mazo A, Alarc\u00f3n-Vila C, Mart\u00ednez-Alarc\u00f3n L, Amores-Iniesta J, Mart\u00edn-S\u00e1nchez F, Ercole GA, Mart\u00ednez CM, Gonz\u00e1lez-Lisorge A, Fern\u00e1ndez-Pacheco J, Mart\u00ednez-Gil P, Adriouch S, Koch-Nolte F, Luj\u00e1n J, Acosta-Villegas F, Parrilla P, Garc\u00eda-Palenciano C, Pelegrin P (2019) P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun 10:2711. https:\/\/doi.org\/10.1038\/s41467-019-10626-x","journal-title":"Nat Commun"},{"key":"10176_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297249","volume":"14","author":"H Mart\u00ednez-Banaclocha","year":"2023","unstructured":"Mart\u00ednez-Banaclocha H, Garc\u00eda-Palenciano C, Mart\u00ednez-Alarc\u00f3n L, Amores-Iniesta J, Mart\u00edn-S\u00e1nchez F, Ercole GA, Gonz\u00e1lez-Lisorge A, Fern\u00e1ndez-Pacheco J, Mart\u00ednez-Gil P, Padilla-Rodr\u00edguez J, Baroja-Mazo A, Pelegr\u00edn P, Mart\u00ednez-Garc\u00eda JJ (2023) Purinergic P2X7 receptor expression increases in leukocytes from intra-abdominal septic patients. Front Immunol 14:1297249. https:\/\/doi.org\/10.3389\/fimmu.2023.1297249","journal-title":"Front Immunol"},{"key":"10176_CR71","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11302-012-9320-9","volume":"8","author":"S Gadeock","year":"2012","unstructured":"Gadeock S, Pupovac A, Sluyter V, Spildrejorde M, Sluyter R (2012) P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cells. Purinergic Signal 8:669\u2013676. https:\/\/doi.org\/10.1007\/s11302-012-9320-9","journal-title":"Purinergic Signal"},{"key":"10176_CR72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0014-5793(03)00172-8","volume":"538","author":"JA Barden","year":"2003","unstructured":"Barden JA, Sluyter R, Gu BJ, Wiley JS (2003) Specific detection of non-functional human P2X7 receptors in HEK293 cells and B-lymphocytes. FEBS Lett 538:159\u2013162. https:\/\/doi.org\/10.1016\/s0014-5793(03)00172-8","journal-title":"FEBS Lett"},{"key":"10176_CR73","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1038\/s41467-023-41338-y","volume":"14","author":"V Bandara","year":"2023","unstructured":"Bandara V, Foeng J, Gundsambuu B, Norton TS, Napoli S, McPeake DJ, Tyllis TS, Rohani-Rad E, Abbott C, Mills SJ, Tan LY, Thompson EJ, Willet VM, Nikitaras VJ, Zheng J, Comerford I, Johnson A, Coombs J, Oehler MK, Ricciardelli C, Cowin AJ, Bonder CS, Jensen M, Sadlon TJ, McColl SR, Barry SC (2023) Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7. Nat Commun 14:5546. https:\/\/doi.org\/10.1038\/s41467-023-41338-y","journal-title":"Nat Commun"},{"key":"10176_CR74","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1002\/cti2.1512","volume":"13","author":"V Bandara","year":"2024","unstructured":"Bandara V, Niktaras VM, Willett VJ, Chapman H, Lokman NA, Macpherson AM, Napoli S, Gundsambuu B, Foeng J, Sadlon TJ, Coombs J, McColl SR, Barry SC, Oehler MK, Ricciardelli C (2024) Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer. Clin Transl Immunology 13:e1512. https:\/\/doi.org\/10.1002\/cti2.1512","journal-title":"Clin Transl Immunology"},{"key":"10176_CR75","doi-asserted-by":"publisher","first-page":"11135","DOI":"10.1074\/jbc.M010353200","volume":"276","author":"BJ Gu","year":"2001","unstructured":"Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, Barden JA, Wiley JS (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276:11135\u201311142. https:\/\/doi.org\/10.1074\/jbc.M010353200","journal-title":"J Biol Chem"},{"key":"10176_CR76","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/s0140-6736(02)08156-4","volume":"359","author":"JS Wiley","year":"2002","unstructured":"Wiley JS, Dao-Ung LP, Gu BJ, Sluyter R, Shemon AN, Li C, Taper J, Gallo J, Manoharan A (2002) A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 359:1114\u20131119. https:\/\/doi.org\/10.1016\/s0140-6736(02)08156-4","journal-title":"Lancet"},{"key":"10176_CR77","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.4049\/jimmunol.172.6.3399","volume":"172","author":"R Sluyter","year":"2004","unstructured":"Sluyter R, Shemon AN, Wiley JS (2004) Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol 172:3399\u20133405. https:\/\/doi.org\/10.4049\/jimmunol.172.6.3399","journal-title":"J Immunol"},{"key":"10176_CR78","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/sj.gene.6364127","volume":"5","author":"R Sluyter","year":"2004","unstructured":"Sluyter R, Dalitz JG, Wiley JS (2004) P2X7 receptor polymorphism impairs extracellular adenosine 5\u2019-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun 5:588\u2013591. https:\/\/doi.org\/10.1038\/sj.gene.6364127","journal-title":"Genes Immun"},{"key":"10176_CR79","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.4049\/jimmunol.171.10.5442","volume":"171","author":"BM Saunders","year":"2003","unstructured":"Saunders BM, Fernando SL, Sluyter R, Britton WJ, Wiley JS (2003) A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing of mycobacteria. J Immunol 171:5442\u20135446. https:\/\/doi.org\/10.4049\/jimmunol.171.10.5442","journal-title":"J Immunol"},{"key":"10176_CR80","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbadis.2018.01.012","volume":"1864","author":"A Ou","year":"2018","unstructured":"Ou A, Gu BJ, Wiley JS (2018) The scavenger activity of the human P2X7 receptor differs from P2X7 pore function by insensitivity to antagonists, genetic variation and sodium concentration: relevance to inflammatory brain diseases. Biochim Biophys Acta Mol Basis Dis 1864:1051\u20131059. https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.012","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10176_CR81","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1164\/rccm.200607-970OC","volume":"175","author":"SL Fernando","year":"2007","unstructured":"Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, Marks GB, Wiley JS, Britton WJ (2007) A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175:360\u2013366. https:\/\/doi.org\/10.1164\/rccm.200607-970OC","journal-title":"Am J Respir Crit Care Med"},{"key":"10176_CR82","doi-asserted-by":"publisher","first-page":"17108","DOI":"10.1074\/jbc.M212759200","volume":"278","author":"JS Wiley","year":"2003","unstructured":"Wiley JS, Dao-Ung LP, Li C, Shemon AN, Gu BJ, Smart ML, Fuller SJ, Barden JA, Petrou S, Sluyter R (2003) An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 278:17108\u201317113. https:\/\/doi.org\/10.1074\/jbc.M212759200","journal-title":"J Biol Chem"},{"key":"10176_CR83","doi-asserted-by":"publisher","first-page":"31287","DOI":"10.1074\/jbc.M313902200","volume":"279","author":"BJ Gu","year":"2004","unstructured":"Gu BJ, Sluyter R, Skarratt KK, Shemon AN, Dao-Ung LP, Fuller SJ, Barden JA, Clarke AL, Petrou S, Wiley JS (2004) An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 279:31287\u201331295. https:\/\/doi.org\/10.1074\/jbc.M313902200","journal-title":"J Biol Chem"},{"key":"10176_CR84","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1096\/fj.201901198RR","volume":"34","author":"KK Skarratt","year":"2020","unstructured":"Skarratt KK, Gu BJ, Lovelace MD, Milligan CJ, Stokes L, Glover R, Petrou S, Wiley JS, Fuller SJ (2020) A P2RX7 single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function. FASEB J 34:3884\u20133901. https:\/\/doi.org\/10.1096\/fj.201901198RR","journal-title":"FASEB J"},{"key":"10176_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/430622","volume":"192","author":"SL Fernando","year":"2005","unstructured":"Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Wiley JS, Britton WJ (2005) Gene dosage determines the negative effects of polymorphic alleles of the P2X7 receptor on adenosine triphosphate-mediated killing of mycobacteria by human macrophages. J Infect Dis 192:149\u2013155. https:\/\/doi.org\/10.1086\/430622","journal-title":"J Infect Dis"},{"key":"10176_CR86","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1096\/fj.12-215368","volume":"27","author":"BJ Gu","year":"2013","unstructured":"Gu BJ, Baird PN, Vessey KA, Skarratt KK, Fletcher EL, Fuller SJ, Richardson AJ, Guymer RH, Wiley JS (2013) A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration. FASEB J 27:1479\u20131487. https:\/\/doi.org\/10.1096\/fj.12-215368","journal-title":"FASEB J"},{"key":"10176_CR87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jpsychires.2009.10.005","volume":"44","author":"S Roger","year":"2010","unstructured":"Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A, Jiang LH (2010) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44:347\u2013355. https:\/\/doi.org\/10.1016\/j.jpsychires.2009.10.005","journal-title":"J Psychiatr Res"},{"key":"10176_CR88","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1161\/hypertensionaha.111.176180","volume":"58","author":"L Stokes","year":"2011","unstructured":"Stokes L, Scurrah K, Ellis JA, Cromer BA, Skarratt KK, Gu BJ, Harrap SB, Wiley JS (2011) A loss-of-function polymorphism in the human P2X4 receptor is associated with increased pulse pressure. Hypertension 58:1086\u20131092. https:\/\/doi.org\/10.1161\/hypertensionaha.111.176180","journal-title":"Hypertension"},{"key":"10176_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0014-5793(01)03311-7","volume":"512","author":"RA Worthington","year":"2002","unstructured":"Worthington RA, Smart ML, Gu BJ, Williams DA, Petrou S, Wiley JS, Barden JA (2002) Point mutations confer loss of ATP-induced human P2X7 receptor function. FEBS Lett 512:43\u201346. https:\/\/doi.org\/10.1016\/s0014-5793(01)03311-7","journal-title":"FEBS Lett"},{"key":"10176_CR90","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1074\/jbc.M211094200","volume":"278","author":"ML Smart","year":"2003","unstructured":"Smart ML, Gu B, Panchal RG, Wiley J, Cromer B, Williams DA, Petrou S (2003) P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem 278:8853\u20138860. https:\/\/doi.org\/10.1074\/jbc.M211094200","journal-title":"J Biol Chem"},{"key":"10176_CR91","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11302-019-09651-8","volume":"15","author":"SR Adhikary","year":"2019","unstructured":"Adhikary SR, Geraghty NJ, Cuthbertson P, Sluyter R, Watson D (2019) Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice. Purinergic Signal 15:177\u2013192. https:\/\/doi.org\/10.1007\/s11302-019-09651-8","journal-title":"Purinergic Signal"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10176-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:09:21Z","timestamp":1787576961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10176-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10176"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10176-0","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ronald Sluyter receives financial support from Qankorey Biotechnology Co. Ltd. Ben J. Gu is the Chief Scientist and a shareholder of Qankorey Biotechnology Co. Ltd.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}